You are here

Special Protocol Assessment for Miraxion in Huntington's Disease Cleared by FDA

LONDON, September 12/PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) procedure for the design of two pivotal Phase III clinical trials of Miraxion(TM) (ultra-pure ethyl-EPA) in Huntington's disease. The Special Protocol Assessment (SPA) is a process under which the FDA provides evaluation and guidance on clinical trial protocols for Phase III trials.

Rick Stewart, Chief Executive Officer of Amarin, commented; "Reaching agreement with the FDA on the trial designs is a positive development for Amarin. This is a major milestone for the company and we look forward to immediate enrollment in the U.S. trial."

The U.S. and European trials will be multi-centre, randomized, double blind, placebo -controlled studies of Miraxion at 43 sites in the U.S. and up to 28 sites in Europe. The trials are expected to involve a total of up to 540 Huntington's disease patients with approximately 300 in the U.S. Phase III trial and approximately 240 in the European Phase III trial over a 6 month period. Patients in the U.S. trial will participate in a further 6-month extension period.

The Huntington Study Group (H.S.G.), based at the University of Rochester, will conduct the U.S. clinical trial on behalf of Amarin. The H.S.G. is a non-profit group of physicians and other health care providers from medical centers in the U.S., Canada, Europe and Australia, experienced in the care of Huntington's disease patients and dedicated to clinical research of Huntington's disease. The European clinical trial will be conducted in collaboration with EURO-HD and ICON, a leading contract research organization (CRO). EURO-HD is a non-profit group of physicians and other healthcare professionals dedicated to the research and care of Huntington's disease patients.

The primary endpoint of the trials will be to determine whether Miraxion taken 2 grams per day (1gram twice daily) results in clinically and statistically significant changes in the Total Motor Score-4 subscale of the Unified Huntington's Disease Rating Scale (UHDRS).

Source: Amarin Corporation

Recent Headlines

Safety concerns include liver injury and interactions with other drugs
No tobacco product is safe, says the lung heath group
Discovery seen as possibly leading to new anti-TB drugs
Study points to permanent hair dye and straighteners
How malaria parasites evade first-line drugs
A new way to fight staph infections
Score could help prevent misuse among cancer patients